0001213900-26-056588
SEC filingRevenue grew 20.7% to $3.5M driven by ZUNVEYL commercial sales, but operating and net losses widened significantly as the company advanced R&D and scaled commercial operations — reflecting a deliberate pivot from licensing to full commercialization.
Operating income declined to -$8.1 million from -$3.7 million in the prior year, a deterioration of 119.6%. This reflects increased time allocation and associated costs for employee and management resources dedicated to developing the dissolvable tablet formulation and executing related clinical studies. The expansion of commercial sales of ZUNVEYL also contributed to higher operating expenses, consistent with management’s stated focus on scaling commercial infrastructure.
Net income decreased to -$6.5 million from -$2.0 million, and diluted EPS declined to $-0.32 from $-0.13. These results reflect both the magnitude of operating losses and the capital structure implications of ongoing financing activity. The YoY changes are aligned with management’s commentary that the company is actively advancing R&D while building commercial capacity — investments that are not yet revenue-generating but are central to long-term value creation.
Net cash used in operating activities totaled -$11.8 million, compared to -$2.0 million in Q1 FY2025. This increase in cash outflow corresponds directly to elevated payroll and SG&A spending required to support ZUNVEYL’s commercial launch and clinical development. Capital expenditures were minimal at $1.3 thousand — down sharply from $63.3 thousand — signaling that near-term capital allocation emphasizes people, programs, and market execution over physical asset investment.
The Company does not have sufficient operating revenue to finance its existing obligations and continues to rely on external financing — including debt and equity raises — to meet working capital needs. Management explicitly states it will need to raise additional capital to fund upcoming R&D, continued commercialization of ZUNVEYL, and general operating costs. Any future capital is expected to further support planned commercial activities, reinforcing that funding strategy is tightly coupled to execution milestones rather than balance sheet optimization.